Telavancin’s “Complete Response” Letter Calls For Pregnancy-Focused REMS
After a three-day, three-drug advisory committee in November, the last sponsor standing - or at least the last to get a "complete response" letter from FDA - may be in the best position to move forward with its complicated skin and skin structure infections antibiotic